Skip to main content

Table 2 PNPC cell survival rates measured by MTT assay

From: Targeted gene therapy of nasopharyngeal cancer in vitro and in vivo by enhanced thymidine kinase expression driven by human TERT promoter and CMV enhancer

Codes and Samples Survival rates
A. Cells without treatment 1
B. Cells transfected with pGL3-basic-EGFP and with GCV treatment 0.984 ± 0.009
C. Cells transfected with pGL3-basic- hTERTp-TK-EGFP-CMV and treated with GCV 0.370 ± 0.024*
D. Cells transfected with pGL3-basic-hTERTp-TK-EGFP-CMV without GCV 0.982 ± 0.010
E. Cells transfected with pGL3-basic-hTERTp-TK-EGFP and treated with GCV 0.533 ± 0.020*
  1. Data are expressed as mean ± standard deviation from three experiments. * indicates p < 0.0001 compared with other groups